Table 2.

Evaluation of the experimental formulation during 12 months of intervention and 6 months of follow up in WOMAC subscales

WOMAC subscales	SBCG1		SBCG2
	Score	Change from baseline	Score	Change from baseline
Pain
Baseline	5.8 (5.2, 6.4) a		5.6 (5.0, 6.2)
3 mo.	1.9 (1.1, 2.8) b	−4.0 (−7.0, −5.1)	2.4 (1.7, 3.2)	−3.2 (−3.9, −2.5)
8 mo.	1.6 (1.0, 2.2)	−4.2 (−9.1, −5.1)	1.5 (1.0, 2.0)	−4.0 (−4.9, −3.2)
12 mo.	1.1 (0.6, 1.7)	−4.5 (−10.5, −5.3)	1.3 (0.8, 1.9)	−4.5 (−5.2, −3.8)
18 mo.	1.2 (0.5, 1.9)	−4.3 (−8.4, −5.3)	1.0 (0.5, 1.5)	−4.8 (−5.6, −4.0)
Stiffness
Baseline	5.9 (5.0, 6.7)		6.3 (5.6, 7.0)
3 mo.	2.0 (1.3, 2.6)	−4.2 (−9.0, −5.1)	2.1 (1.3, 2.9)	−4.0 (−4.9, −3.2)
8 mo.	1.0 (0.5, 1.5)	−4.8 (−9.3, −5.8)	1.5 (0.9, 2.0)	−4.8 (−5.7, −3.8)
12 mo.	0.5 (0.2, 0.9)	−5.2 (−10.7, −6.2)	1.3 (0.6, 2.0)	−4.9 (−5.9, −4.0)
18 mo.	0.7 (0.0, 1.4)	−5.0 (−7.9, −6.3)	1.1 (0.4, 1.7)	−5.0 (−6.0, −4.0)
Physical functioning
Baseline	5.9 (5.2, 6.6)		6.2 (5.4, 6.9)
3 mo.	2.1 (1.5, 2.8)	−3.8 (−7.6, −4.9)	2.1 (1.5, 2.8)	−3.8 (−4.5, −3.1)
8 mo.	1.4 (0.9, 1.9)	−4.6 (−10.2, −5.5)	1.5 (1.1, 2.0)	−4.7 (−5.6, −3.9)
12 mo.	0.6 (0.4, 0.9)	−5.1 (−13.3, −5.9)	1.2 (0.6, 1.7)	−5.2 (−6.1, −4.3)
18 mo.	0.7 (0.3, 1.2)	−4.8 (−9.6, −5.9)	1.0 (0.5, 1.4)	−5.2 (−6.2, −4.3)
Global score
Baseline	17.5 (15.7, 19.3)		18.1 (16.3, 19.9)
3 mo.	6.0 (4.2, 7.9)	−11.9 (−9.1, −14.7)	6.7 (4.7, 8.7)	−11.1 (−13.1, −9.1)
8 mo.	4.2 (2.7, 5.6)	−13.5 (−10.4, −16.1)	4.5 (3.1, 5.9)	−13.6 (−15.9, −11.2)
12 mo.	2.3 (1.5, 3.1)	−14.8 (−14.2, −17.0)	3.8 (2.1, 5.5)	−14.6 (−16.9, −12.4)
18 mo.	2.6 (0.8, 4.4)	−14.0 (−9.7, −17.1)	3.1 (1.5, 4.6)	−15.0 (−17.5, −12.6)

^aAll values are means (95% confidence interval).

^bAll post-treatment measurements were significantly different from baseline value. There were no significant differences between treatments.